Woodford Investment Management now holds 25.4% in the Aim-listed stock, according to a regulatory filing published on Tuesday.
In June, the company’s stock soared 114% when it announced its FLU-v treatment had delivered positive results in a phase two trial, whereby the optimal dosage of the drug is determined.
Woodford held 18.6% at the time.
In the period since, the stock rallied 47.4% to 101p on 5 July, a day before Woodford upped his stake from 24.2%, the regulatory filing said. It has since fallen to 78.8p at close of play on Monday.
Meanwhile, IP Group, which represents 3% of the Woodford Equity Income fund, has been reducing its stake in the pharmaceutical company over the period.
Its stake is now 16.7%, according to a filing published on Friday. The group held 20.7% on 22 June, shortly after the company’s stock rallied in response to the successful drug trial.
Its founder, David Norwood, has also reduced his stake from 4.12% to less than 3%.
IP Group commercialises life sciences and cleantech research produced out of UK universities.
Woodford’s stake is rivaling that of his former employer Invesco, which held 27.2%, according to figures on Hvivo’s website from 25 June.
The Woodford Investment Management website only shows holdings to the period ended 31 May, whereby the Equity Income fund held 0.4%.
